File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hyperlipidemia after renal transplantation: Treatment with gemfibrozil

TitleHyperlipidemia after renal transplantation: Treatment with gemfibrozil
Authors
Issue Date1994
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/NEF
Citation
Nephron, 1994, v. 67 n. 3, p. 317-321 How to Cite?
AbstractThirty-eight renal allograft recipients who had persistent hyperlipidemia and stable renal function 27.8 ± 18.2 months after renal transplantation were treated with gemfibrozil. Gemfibrozil therapy resulted in a decrease in the levels of total cholesterol (TC; 297.6 ± 41.0 mg/dl to 249.2 ± 43.7 mg/dl, -16.3%; p<0.0001), triglyceride (TG; 231.9 ± 116.8 to 125.7 ± 58.4 mg/dl, -45.8%, P<0.0005), and LDL-choiesterol (LDL-C; 203.8 ± 37.4 to 174.5 ± 42.5 mg/dl, -14.4%; p = 0.001), which were sustained for 29.1 ± 16.0 months. Comparison of sequential lipid profiles between gemfibrozil-treated individuals and untreated hyperlipidemic controls matched for age, sex, time after transplantation, and the degree of hyperlipidemia, showed that gemfibrozil-treated patients had lower levels of TC (239.9 ± 39.5 vs. 272.8 ± 34.1 mg/dl; P<0.005), TG (125.7 ± 67.3 vs. 167.3 ± 69.0 mg/dl; p<0.05), and LDL-C (160.2 ± 41.3 vs. 185.3 ± 26.6 mg/dl; p<0.05) on serial follow-up. No significant side-effect was observed with gemfibrozil therapy. Our data showed that gemfibrozil was a safe and effective drug for the treatment of hyperlipidemia in renal allograft recipients, which could reduce these patients's long-term cardiovascular risks.
Persistent Identifierhttp://hdl.handle.net/10722/77882
ISSN
2004 Impact Factor: 1.462
2006 SCImago Journal Rankings: 0.715
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.contributor.authorCheng, IKPen_HK
dc.contributor.authorTam, SCFen_HK
dc.date.accessioned2010-09-06T07:36:47Z-
dc.date.available2010-09-06T07:36:47Z-
dc.date.issued1994en_HK
dc.identifier.citationNephron, 1994, v. 67 n. 3, p. 317-321en_HK
dc.identifier.issn0028-2766en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77882-
dc.description.abstractThirty-eight renal allograft recipients who had persistent hyperlipidemia and stable renal function 27.8 ± 18.2 months after renal transplantation were treated with gemfibrozil. Gemfibrozil therapy resulted in a decrease in the levels of total cholesterol (TC; 297.6 ± 41.0 mg/dl to 249.2 ± 43.7 mg/dl, -16.3%; p<0.0001), triglyceride (TG; 231.9 ± 116.8 to 125.7 ± 58.4 mg/dl, -45.8%, P<0.0005), and LDL-choiesterol (LDL-C; 203.8 ± 37.4 to 174.5 ± 42.5 mg/dl, -14.4%; p = 0.001), which were sustained for 29.1 ± 16.0 months. Comparison of sequential lipid profiles between gemfibrozil-treated individuals and untreated hyperlipidemic controls matched for age, sex, time after transplantation, and the degree of hyperlipidemia, showed that gemfibrozil-treated patients had lower levels of TC (239.9 ± 39.5 vs. 272.8 ± 34.1 mg/dl; P<0.005), TG (125.7 ± 67.3 vs. 167.3 ± 69.0 mg/dl; p<0.05), and LDL-C (160.2 ± 41.3 vs. 185.3 ± 26.6 mg/dl; p<0.05) on serial follow-up. No significant side-effect was observed with gemfibrozil therapy. Our data showed that gemfibrozil was a safe and effective drug for the treatment of hyperlipidemia in renal allograft recipients, which could reduce these patients's long-term cardiovascular risks.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/NEFen_HK
dc.relation.ispartofNephronen_HK
dc.rightsNephron. Copyright © S Karger AG.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshCholesterol - blooden_HK
dc.subject.meshCholesterol, LDL - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGemfibrozil - therapeutic useen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHyperlipidemias - blood - drug therapy - etiologyen_HK
dc.subject.meshKidney Transplantation - adverse effectsen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshTriglycerides - blooden_HK
dc.titleHyperlipidemia after renal transplantation: Treatment with gemfibrozilen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0028-2766&volume=67&spage=317&epage=321&date=1994&atitle=Hyperlipidemia+after+renal+transplantation:+treatment+with+gemfibrozilen_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid7936022-
dc.identifier.scopuseid_2-s2.0-0028307252en_HK
dc.identifier.hkuros5583en_HK
dc.identifier.volume67en_HK
dc.identifier.issue3en_HK
dc.identifier.spage317en_HK
dc.identifier.epage321en_HK
dc.identifier.isiWOS:A1994NU11000010-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridCheng, IKP=7102537483en_HK
dc.identifier.scopusauthoridTam, SCF=7202037323en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats